Estrella immunopharma inc ESLA.US 總覽分析
ESLA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ESLA 近期報酬表現
-0.97%
Estrella immunopharma inc
4.57%
同產業平均
3.26%
S&P500
與 ESLA 同產業的標的表現
- ADTX Aditxt inc價值 1 分趨勢 2 分波段 2 分籌碼 -股利 1 分查看更多
ESLA 公司資訊
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).